Research programme: ion channel modulators - Luc Therapeutics/Saniona

Drug Profile

Research programme: ion channel modulators - Luc Therapeutics/Saniona

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Aniona
  • Developer Luc Therapeutics; Saniona
  • Class Small molecules
  • Mechanism of Action Small conductance calcium-activated potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Ataxia

Most Recent Events

  • 06 Mar 2017 Ataxion has merged with Luc Therapeutics forming Luc Therapeutics
  • 06 Mar 2017 Ataxion and Luc Therapeutics merger terminates Biogen's option to acquire the programme for Ataxia
  • 20 Mar 2014 Aniona is now called Saniona
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top